TL;DR
Kivo Health raised $10 million in a Series A round led by Allumia Ventures, bringing the company’s reported total financing to $16 million. The Seattle startup plans to expand its virtual home-care program for COPD nationwide and says it aims to reach tens of thousands of patients over the next two years.
Seattle-based Kivo Health raised $10 million in a Series A financing round to expand its at-home virtual care program, which currently focuses on chronic obstructive pulmonary disease, or COPD. The round, led by Allumia Ventures, brings the company’s total financing to $16 million, according to Home Health Care News.
Additional investors in the round include Corewell Health Ventures, Y Combinator, Heuristic Capital and MassMutual Ventures. Kivo says the new capital will support expansion across the United States. Co-founder and CEO Victor Sadauskas told Home Health Care News that the company plans to deliver care to tens of thousands of patients over the next two years.
Kivo’s program combines home-use equipment and personalized treatment plans. After enrolling, a patient receives a kit that includes a tablet, an oxygen monitor and exercise bands, then meets virtually with a respiratory therapist for an assessment and care plan. Patients subsequently attend small-group virtual sessions with respiratory therapists twice a week for nine weeks, according to the company’s website.
The sessions cover breathing techniques, targeted exercises and COPD management resources. Kivo says its program is covered by Medicare, Medicaid and several commercial health plans, including UnitedHealthcare, Humana, Blue Cross, Aetna and Priority Health. The source report did not provide a breakdown of how many members are covered by each plan or how many are currently enrolled.
Scaling Care Beyond Clinic Visits
The financing gives Kivo capital to pursue a wider patient reach with a model intended to support people between in-person clinical visits. COPD is the company’s starting point, and Kivo says it wants to help older adults receive earlier intervention and manage symptoms at home. Whether broader availability leads to better outcomes will depend on execution, access through health plans and evidence from the program.
Kivo also says its approach can reduce avoidable hospitalizations, emergency department visits and nursing home stays. The company claims it saves health plans $8,245 per member per year, but the report does not supply the methodology, comparison group or study details behind that estimate. The figure should be understood as a company-reported claim, not an independently established result in the available material.
The stated plan to expand to other high-cost chronic illnesses could broaden the company’s business beyond lung disease. Kivo has not identified which conditions it may target or when it expects to add them.
How Kivo’s COPD Program Works
Kivo describes its service as AI-powered virtual home care for chronic lung disease, beginning with COPD. Its care model uses remote sessions with respiratory therapists alongside equipment intended for home use. The reported treatment schedule runs for nine weeks, with patients meeting in small groups twice each week.
The company says the program is available through Medicare, Medicaid and commercial insurers. The funding announcement follows an earlier financing history that, with this round, puts Kivo’s reported total raised at $16 million. Home Health Care News reported that the company has delivered tens of thousands of sessions and served thousands of patients, citing Sadauskas; those figures were not independently verified in the source material.
“We plan to expand nationwide to deliver care to tens of thousands of patients in the next two years.”
— Victor Sadauskas, Kivo Health co-founder and CEO, speaking to Home Health Care News
Expansion Plans and Savings Evidence
The announcement does not specify how the $10 million will be allocated, which regions Kivo will enter first or whether the company has set intermediate expansion milestones. It also does not state how many additional patients it expects to enroll during each year of the two-year target.
Details supporting Kivo’s reported savings of $8,245 per member annually are not included in the source report. It is unclear what population or period the calculation covers, what costs are counted, and whether the estimate has been evaluated by an independent party. The report also does not detail the company’s AI tools or their role in treatment decisions.
National Rollout Over Two Years
Kivo says it intends to expand nationwide over the next two years, with a goal of providing care to tens of thousands of patients. The company has not disclosed a rollout calendar, specific new markets or enrollment targets by health plan. Its stated next areas of development include adapting its care model for other high-cost chronic illnesses, though no conditions or launch dates have been named.
Further information about geographic availability, patient enrollment and independently reviewed outcomes would help clarify how quickly the program is growing and whether its claimed cost and health benefits are being achieved. For now, the confirmed development is the financing round and the company’s stated expansion plans.
Key Questions
How much did Kivo Health raise?
Kivo raised $10 million in Series A financing. The round brings its total reported financing to $16 million.
Who led the funding round?
Allumia Ventures led the round. Additional investors included Corewell Health Ventures, Y Combinator, Heuristic Capital and MassMutual Ventures.
What care does Kivo provide?
Kivo provides virtual home care for chronic lung disease, beginning with COPD. Its program includes home equipment, an assessment with a respiratory therapist and twice-weekly small-group virtual sessions over nine weeks.
Which insurers cover the program?
Kivo says its program is covered by Medicare, Medicaid, UnitedHealthcare, Humana, Blue Cross, Aetna and Priority Health, among other major health plans.
What remains unknown about the expansion?
Kivo has not named its first new markets, provided a detailed rollout schedule or explained how it calculated its claimed $8,245 in annual savings per member.
Source: homehealthcarenews.com
